• Xeris Biopharma director Barbara-Jean Anne Bormann-Kennedy sold 16,000 common shares on June 4 at USD 6.09.
• Directly held common shares rose to 150,693, reflecting receipt of 24,193 shares at USD 0.
• She also received stock options for 32,996 shares with an exercise price of USD 6.15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001635065-26-000002), on June 05, 2026, and is solely responsible for the information contained therein.